One-Shot gene therapy could free patients from monthly eye injections
Disease control
Not yet recruiting
This early-stage study is testing a new one-time gene therapy called EXG202 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can safely deliver a vision-protecting protein long-term, potentially replacing the…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Jiayin Biotech Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC